CTOR

+ Watchlist + Portfolio

Citius Oncology, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.75
52-Week Range: $0.49 – $2.25
Market Cap: $80.28M
P/E (TTM): —
EPS (TTM): -0.48
Dividend Yield: —

Advanced Metrics

Price/Book: 1.41
PEG Ratio: —
Return on Equity: -119.90%
Return on Assets: -28.31%
Gross Margin: 80.07%
Operating Margin: -1716.17%
Profit Margin: 0.00%
Current Ratio: 0.50
Debt/Equity: 0.11
Total Debt: $3.80M
Free Cash Flow: $-23.62M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $85.76M

CTOR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.43M	$4.24M	$4.93M	$6.42M
Selling, General & Admin	$1.43M	$7.88M	$15.65M	$17.10M
Operating Expenses	$4.86M	$12.12M	$20.57M	$23.52M
Operating Income	-$4.86M	-$12.12M	-$20.57M	-$23.52M
EBITDA	-$4.86M	-$12.12M	-$20.57M	-$23.49M
Pretax Income	-$4.86M	-$12.12M	-$20.57M	-$23.70M
Income Tax	$576.00K	$576.00K	$576.00K	$1.06M
Net Income	-$5.43M	-$12.70M	-$21.15M	-$24.76M
Diluted EPS	-0.08	-0.18	-0.31	-0.34
Diluted Shares	71.24M	71.24M	68.05M	73.27M

CTOR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$0.00	$0.00	$112.00	$3.92M
Inventory	—	$0.00	$8.27M	$22.29M
Current Assets	$2.69M	$7.73M	$10.97M	$27.54M
Total Assets	$42.69M	$47.73M	$84.37M	$100.94M
Current Liabilities	$5.85M	$21.05M	$32.70M	$49.49M
Long-Term Debt	—	—	$3.80M	$3.80M
Total Debt	—	—	$3.80M	$3.80M
Total Liabilities	$6.42M	$22.20M	$38.23M	$56.08M
Retained Earnings	-$5.43M	-$18.13M	-$39.28M	-$64.04M
Shareholders' Equity	$36.27M	$25.54M	$46.14M	$44.87M
Working Capital	-$3.16M	-$13.31M	-$21.73M	-$21.95M
Net Debt	—	—	$3.80M	—

CTOR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$0.00	$0.00	$126.35K	-$5.49M
Capital Expenditure	—	—	-$5.00M	-$5.75M
Free Cash Flow	$0.00	$0.00	-$4.87M	-$11.24M
Stock-Based Compensation	$0.00	$1.97M	$7.50M	$8.32M
Investing Cash Flow	—	$0.00	-$5.00M	-$5.75M
Financing Cash Flow	—	$0.00	$4.87M	$15.17M
Net Change in Cash	—	—	$112.00	$3.92M

CTOR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$3.94M	$1.67M
Cost of Revenue	$0.00	—	—	$789.21K	$328.88K
Gross Profit	$0.00	—	—	$3.15M	$1.34M
Research & Development	$3.14M	$938.28K	$1.08M	$1.02M	$1.08M
Selling, General & Admin	$4.33M	$4.01M	$3.64M	$6.82M	$27.15M
Operating Expenses	$7.47M	$4.94M	$4.71M	$8.41M	$29.95M
Operating Income	-$7.47M	-$4.94M	-$4.71M	-$5.25M	-$28.61M
EBITDA	-$7.47M	-$4.94M	-$4.68M	-$4.65M	-$25.09M
Pretax Income	-$7.47M	-$5.11M	-$4.73M	-$5.27M	-$26.84M
Income Tax	$264.24K	$264.24K	$264.24K	$264.24K	-$231.21K
Net Income	-$7.74M	-$5.37M	-$5.00M	-$5.53M	-$26.61M
Diluted EPS	-0.11	-0.08	—	-0.06	-0.27
Diluted Shares	71.55M	71.55M	—	87.46M	100.03M

CTOR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$112.00	$112.00	$3.92M	$7.30M	$2.63M
Receivables	—	—	—	$4.05M	$1.08M
Inventory	$15.34M	$17.21M	$22.29M	$22.64M	$22.66M
Current Assets	$18.04M	$18.31M	$27.54M	$37.15M	$29.42M
Total Assets	$91.44M	$91.71M	$100.94M	$109.97M	$100.70M
Current Liabilities	$49.74M	$52.99M	$49.49M	$44.71M	$58.81M
Long-Term Debt	$3.80M	$3.80M	$3.80M	$3.80M	$3.80M
Total Debt	$3.80M	$3.80M	$3.80M	$3.80M	$3.80M
Total Liabilities	$55.80M	$59.31M	$56.08M	$51.56M	$65.43M
Retained Earnings	-$53.67M	-$59.04M	-$64.04M	-$69.57M	-$96.18M
Shareholders' Equity	$35.64M	$32.40M	$44.87M	$58.41M	$35.27M
Working Capital	-$31.70M	-$34.68M	-$21.95M	-$7.56M	-$29.39M
Net Debt	$3.80M	$3.80M	—	—	$1.17M

CTOR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	$0.00	$0.00	-$5.49M	-$7.35M	-$3.83M
Capital Expenditure	—	—	—	-$4.40M	-$600.00K
Free Cash Flow	$0.00	$0.00	-$11.24M	-$11.75M	-$4.43M
Depreciation & Amortisation	$0.00	—	—	$573.44K	$1.72M
Stock-Based Compensation	$2.09M	$2.13M	$2.30M	$3.96M	$3.53M
Investing Cash Flow	$0.00	—	—	-$4.40M	-$600.00K
Financing Cash Flow	$0.00	—	—	$15.13M	-$231.20K
Net Change in Cash	—	—	—	$3.37M	-$4.66M

Market Snapshot

About

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing anti-cancer therapies. The company is headquartered in Cranford, New Jersey. Citius Oncology's pipeline includes novel treatments targeting solid tumors and hematological malignancies. The company emphasizes innovative drug formulations and combination therapies designed to improve patient outcomes in oncology.